Ophiomics was born from a collaboration between scientists with clinicians sharing the purpose of bringing the latest advances in genomics, bioinformatics and clinical research in support of a Precision Oncology.

Ophiomics develops and offers advanced genetic and genomic tests in support of diagnostic, prognostic, pharmacogenomics and clinical follow up. We process both FFPE and Liquid Biospies (based on circulating cell free DNA) to characterise mutational landscapes of tumours, providing guidance for therapy and non-invasive assessments of response to treatment. We offer clinical testing to cancer centres alongside a strong emphasis in clinically-oriented research.